The Commerce Department on Thursday (Dec. 7) released a draft framework explaining how the administration will start considering cost for the first time in deciding whether to march in on patents of taxpayer-funded drugs and other inventions, and the document promptly drew fire from both drug-pricing advocates who say it doesn’t go far enough and industry and GOP lawmakers on the other side who vow to fight the latest government intervention in drug prices. Senate health committee chair Bernie Sanders...